About
About The United Laboratories International Holdings Limited
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-infection, and other human-used finished products, including ophthalmic drugs, topical dermatological drugs, etc.; and health and wellness products, such as general dietary supplements, healthcare food products, cross-border nutritional supplements, and medical and aesthetic skincare products for various categories comprising bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection, and immunity enhancement. Further, it is involved in the research and development, production, sale, and technical services of economic and companion animal medicines for livestock, poultry, and aquatic products and pets. The company has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The United Laboratories International Holdings Limited was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
Visit company website
5 years, 5 months ago
The United Laboratories International Holdings Limited is currently in a long term downtrend where the price is trading 8.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
The United Laboratories International Holdings Limited's total revenue rose by 0.0% to $4B since the same quarter in the previous year.
Its net income has dropped by 41.4% to $203M since the same quarter in the previous year.
Finally, its free cash flow grew by 216.1% to $341M since the same quarter in the previous year.
Based on the above factors, The United Laboratories International Holdings Limited gets an overall score of 3/5.